相关实验视频

Updated: May 5, 2026

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

奇川可以通过抑制PI3K/Akt/mTOR信号通路来缓解便秘:一个综合网络药理学和实验研究

Xiang Bao¹, Yunyun Chen¹, Qianying Zhu²

¹Department of Proctology, Zhongda Hospital Southeast University, No. 87 Dingjiaqiao, Nanjing, 210000, China.

Scientific reports

|March 3, 2026

概括

奇川开 (JCD) 通过向关键分子通路,有效治疗慢性便秘. 这项研究揭示了JCD.

科学领域:

药理学药理学是指药理学的学科.
胃肠病学胃肠病学
传统中国医药传统中国医药

背景情况:

慢性便秘影响全球健康,降低生活质量.
吉川开 (JCD) 是一种用于治疗便秘的中国传统医学 (TCM).
对于JCD的抗便秘作用的分子机制尚不清楚.

研究的目的:

为了阐明Jichuan Decoction (JCD) 在治疗便秘方面的分子机制.
整合网络药理学,分子对接和体内实验.
确定关键的目标和途径涉及到JCD的有效性.

主要方法:

网络药理学确定了生物活性化合物和治疗点.
分子对接评估了JCD化合物和标之间的结合亲缘关系.
在体内实验中使用了洛佩拉胺诱导的老鼠便秘模型.
基因和基因组的京都百科全书 (KEGG) 途径分析.

主要成果:

在JCD中确定了41种生物活性化合物和20种与便秘相关的标,其中MTOR和PTGS2是核心目标.
在JCD成分和核心目标之间观察到强烈的结合亲和力.
在老鼠中,联合疾病治疗改善了便秘症状,并恢复了肠道功能.
在体内,JCD抑制了PI3K/Akt/mTOR信号通路.

结论:

奇川开 (JCD) 通过多目标调制产生抗便秘作用.
PI3K/Akt/mTOR信号通路是JCD的作用机制的核心.
这项研究将TCM的实证使用与用于便秘治疗的现代药理学验证相结合.

关键词:

便秘便秘便秘便秘奇川的蒸奇川的蒸网络药理学网络药理学在PI3K/Akt/mTOR路径中.

更多相关视频

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

相关概念视频

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...